Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Axsome Therapeutics' Amortizatization of Intangibles rose 6.23% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 26.6%. This contributed to the annual value of $6.4 million for FY2024, which is 26.67% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Amortizatization of Intangibles of $1.6 million as of Q3 2025, which was up 6.23% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Amortizatization of Intangibles registered a high of $1.6 million during Q3 2022, and its lowest value of $275000.0 during Q1 2022.
  • In the last 4 years, Axsome Therapeutics' Amortizatization of Intangibles had a median value of $1.6 million in 2023 and averaged $1.5 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first soared by 48181.82% in 2023, then tumbled by 106.99% in 2025.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Amortizatization of Intangibles stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.6 million for Q2 2025, and $1.6 million during Q1 2025.